An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

NCT01902862 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Recruitment too slow

Conditions

Lymphoma, Follicular

Interventions

DRUG: Bortezomib
DRUG: Rituximab

Sponsor

Janssen-Cilag G.m.b.H